Panacea Global, Inc. (PGI) is a biotechnology company focusing on developing and commercializing products for the early detection, diagnosis and monitoring the recurrence of cancer. We have developed a blood test that can detect the presence of cancer in humans using a novel cancer biomarker named Human Aspartyl (Asparaginyl) B-Hydroxylase (HAAH), an enzyme which is over expressed in cancer cells and is the foundation of our breakthrough technology. PGI offers patients with highly accurate, reliable, fast and cost-effective cancer detection tests, which can be used for early diagnosis, remission and recurrence of cancer following treatment. PGI is currently at the stage of launching its products that includes diagnostics for breast, colon, prostate, and lung cancers, which make up over 80% of cases of cancer.

• Headquartered in Toronto, Ontario, Canada.
• Publicly traded on the OTCBB under the symbol, PANG. PGI.
• Has worldwide exclusive rights (excluding the USA) attained from Panacea Pharmaceuticals, Inc. to distribute and commercialize its cancer diagnostic tests.
• PGI’s diagnostic tests are regarded as revolutionary.
• Can diagnose cancer at an early stage using a blood serum with high sensitivity/specificity, fast turnaround (within 72 hours).
• Relatively inexpensive and non-invasive.
• Early diagnosis and treatment of cancer can play a key role in increasing patient’s chances of survival.
• However, current cancer diagnostic modalities are still not accurate, may take up to several months to obtain results and the associated costs are extremely high.
• The technology is protected by over 50 patents/patent applications worldwide.
• HAAH can be used in blood tests to determine if a patient has cancer.
• The blood test can be formatted for use on automated instrumentation typically found in large clinical and hospital laboratories or manually.
• PGI’s current product line will be operating in the “new generation diagnostics market” projected to be valued at over $5 billion by 2015.
• Projected net revenues to PGI after 5 years, in 2017 are expected to be around $350 - 375 million.
• PGI’s corporate development strategy involves the development and sustainment of regional partnerships through exclusive licensing agreements.